May 26, 2013

RELAX-AHF shows first positive findings in HFpEF patients, VIVIDD reveals vildagliptin non-inferior to placebo



Results of both late breaking trials presented at Heart Failure 2013

Serelaxin may be more effective for relieving dyspnea in heart failure with preserved ejection fraction (HFpEF) than reduced (HFrEF) during the first 24 hours, according to results from RELAX-AHF presented in today’s late breaking trial session(1) at the Heart Failure Congress 2013. Results were also presented from VIVIDD, the first trial of the anti-diabetes drug vildagliptin in patients with heart failure(2).

The Heart Failure Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology and is being held 25-28 May in Lisbon, Portugal.